Inclusion Criteria:

          1. Written informed consent obtained prior to any study-specific procedure

          2. Female or male age ≥ 18 years

          3. Able to comply with the protocol

          4. Histologically or cytologically confirmed, HER2 (human epidermal growth factor 2)
             -negative, men or women with breast adenocarcinoma

          5. WHO performance status ≤ 2

          6. Adequate hematological function Absolute neutrophil count (ANC) ≥1.0 x 109/L AND
             Platelet count ≥100 x 109/L AND Hemoglobin ≥ 10 g/dL (may be transfused to maintain or
             exceed this level)

          7. Adequate liver function Total bilirubin <1.5 x upper limit of normal (ULN) AND AST
             (aspartate aminotransferase), ALT (alanine aminotransferase) <2.5 x ULN (in cohort I);
             AST, ALT <5 x ULN (in cohort II)

          8. Adequate renal function Serum creatinine ≤1.25 x ULN (and if measured: Creatinine
             clearance within normal reference values)

          9. Women should not be pregnant or breast-feeding. Women with an intact uterus (unless
             amenorrhoeic for the last 24 months and premenopausal levels of FSH (follicle
             stimulating hormone), LH (luteinizing hormone) and oestradiol) must have a negative
             serum pregnancy test within 28 days prior to inclusion into the study.

        Exclusion Criteria:

          1. Previous chemotherapy treatment for localized breast cancer less than 24 months before
             inclusion into study (cohort I) or metastatic breast cancer treated with taxane
             (cohort II).

          2. Other earlier or concomitant carcinoma less than five years prior to the breast cancer
             diagnosis, except for basal cell carcinoma, in situ cervix cancer or breast cancer

          3. Clinically significant (i.e. active) cardiovascular disease for example cardiovascular
             accident (≤6 months before enrolment), myocardial infarction (≤6 months before
             enrolment), unstable angina, congestive heart failure (CHF) NYHA (New York Heart
             Association) Class ≥II, serious cardiac arrhythmia requiring medication during the
             study, which might interfere with regularity of the study treatment, or not controlled
             by medication

          4. Treatment with any other investigational agent, or participation in another clinical
             intervention trial within 21 days prior to enrolment

          5. Evidence of any other disease, neurological or metabolic dysfunction, physical
             examination finding or laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates the use of an investigational drug or puts the patient
             at high risk for treatment-related complications.